#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

The treatment of Waldenström macroglobulinemia and the therapy of diseases caused by monoclonal IgM gammaglobulin


Authors: Z. Adam 1;  V. Ščudla 2;  Z. Kořístek 1
Authors‘ workplace: Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Vorlíček, CSc. 1;  III. interní klinika Lékařské fakulty UP a FN Olomouc, přednosta prof. MUDr. Vlastimil Ščudla, CSc. 2
Published in: Vnitř Lék 2008; 54(1): 68-83
Category: Review

Overview

Waldenström macroglobulinemia is defined by the presence of IgM type monoclonal immunoglobulin and histological prove of lymphoplasmocytary lymphoma in the bone marrow. Alkylating cytostatic drugs, chlorambucil or cyclofosfamide in monotherapy have been typically used for its treatment. Similarly to other lymphoproliferative diseases with a low degree of aggressiveness, purine analogues (fludarabine and 2-chlordeoxyadenosine) have a faster treatment response and a higher number of treatment responses, especially if administered in combination with alkylating drugs. The monoclonal antibody rituximab (R) also brings considerable improvement to patients suffering from the disease. It is good for cytopenic patients on monotherapy, and for non-cytopenic patients, in combination with other drugs, both with R-CHOP and with a purine analogue and an alkylating cytostatic drug. In recent years, new drugs for the treatment of this disease have been tested (bortezomib, thalidomid, revlimid and others). High-dose chemotherapy with autologous transplantation has a higher treatment response rate than classical chemotherapy. It is recommended in case of insufficient effect of conventional treatment or early relaps. Young patients with suitable profile and insufficient response to conventional treatment can also qualify for allogenic transplantation; graft response against the disease has been observed in almost all patients who underwent allogenic transplantation. However, treatment is often necessary also in diseases caused by IgM monoclonal immunoglobulin, irrespective of it being formed by a malignant or a benign clone, because the characteristics of IgM monoclonal immunoglobulin may endanger the patient’s integrity. The article provides an overview of treatment options for Waldenström macroglobulinemia and diseases caused by monoclonal IgM.

Keywords:
Waldenström macroglobulinemia – diseases caused by monoclonal immunoglobulin – disease of cold agglutinins – cryoglobulinemia – hyperviscosity


Sources

1. Waldenström J. Incipient myelomatosis or essential hyperglobulinemia with fibrinogenopenia. A new syndrome? Acta Med Scand 1944; 117: 217-247.

2. Pangalis GA, Kyrtsonis MCh, Kontopidu FN et al. Differential diagnosis of Waldenström’s macroglobulinemia and other B cell disorders. Clin Lymphoma 2005; 5: 235-240.

3. Rajkumar SV Monoclonal gammopathy of unknown significance, Waldenström’s macroglobulinaemia, AL-amyloidosis and related plasma cell disorders. Diagnosis and treatment. Mayo Clin Proc 2006; 81: 893-703.

4. Johnson SA, Birchall J, Luckie C et al. Guidelines on management of Waldenström’s macroglobulinemia. Brit J Haematol 2006; 132: 687-697.

5. Kyle RA, Treon SP, Alexanian R et al: Prognostic markers and criteria to initiate therapy in Waldenström´s macroglobulinemia. Consensus panel recommendation from the second international Workshop on Waldenström´s macroglobulinemia. Semin Oncol 2003; 30: 116-120.

6. Kimby E, Treon SP, Anagnastopoulos A et al. Update on recommendations for assessing response from the Third International Workshop on Waldenström’s macroglobulinaemia. Clin Lymphoma Myeloma 2006; 6: 380-383.

7. Weber D, Treon SP, Emmanouilides Ch et al. Uniform response criteria in Waldenström’s macroglobulinemia: Consensus panel recommendations from the second international workshop on Waldenström’s macroglobulinemia. Sem Oncol 2003; 30: 127-131.

8. Kyle RA, Greipp PR, Gerz MA et al. Waldenström’s macroglobulinemia. A prospective study comparing daily with intermittent oral chlorambucil. Brit J Haematol 2000; 108: 737-742.

9. Kyle RA, Treon SP, Alexanian R et al: Prognostic markers and criteria to initiate therapy in Waldenström’s macroglobulinemia. Consensus panel recommendation from the second international Workshop on Waldenström´s macroglobulinemia. Semin Oncol 2003; 30: 116-120.

10. Dimopoulos MA, Kyle RA, Anagnastopoulos A et al. Diagnosis and management of Waldenström’s macroglobulinemia. J Clin Oncol 2005; 23: 1564-1577.

11. Dimopoulos MA, Merlini G, Leblond V et al. How we treat Waldenström’s macroglobulinemia. Haematologica 2005; 90: 117-125.

12. Annibali O, Petruci MT, Martini V et al. Treatment of 72 newly diagnosed Waldenström’s macroglobulinemia cases with oral melphalan, cyclophosphamide and prednisone. Cancer 2005; 103: 582-587.

13. Johnson SA. Waldenström macroglobulinaemia. Rev Clin Exp Hematol 2002; 6: 421-334.

14. Gertz MA, Anagostopoulos A, Anderson K et al. Treatment recommendation in Waldenström’s macroglobulinaemia. Consensus panel recommendation from the second international workshop on Waldenström’s macroglobulinaemia. Semin Oncol 2003; 30: 121-126.

15. Treon SP, Gertz MA, Dimopoulos M et al. Update on treatment recommendations from the Third International Worshop on Waldenström’s macroglobulinaemia. Blood 2006; 107: 3442-3446.

16. Björkholm M. Treatment options in Waldenström’s macroglobulinemia. Clin Lymphoma 2004; 5: 155-162.

17. Desikan KR, Li Z, Jaganath S. Waldenström’s makroglobulinemia: current therapy and future approaches. Bio Drugs 2002; 16: 201-207.

18. Dimopoulos MA, Merlini G, Leblond V et al. How we treat Waldenström’s macroglobulinemia. Haematologica 2005; 90: 117-125.

19. O’Reilly RA, MacKanzie MR. Primary macroglobulinaemia: remission with adrenal corticosteroid therapy. Arch Intern Med 1967; 44: 889-890.

20. Jane SM, Salem HH. Treatment of resistant Waldenström’s macroglobulinaemia with high dose glucocorticosteroids. Aust NZJ Med 1988; 18: 77-78.

21. Hensel M, Villalobos M, Kornacker M et al. Pentostatin/cyclophosphamide with or without rituximab: An effective regimen for patients with Waldenström’s macroglobulinemia/lymphoplasmocytic lymphoma. Clin Lymphoma Myeloma 2005; 6: 131-135.

22. Dhodapkar MV, Jacobson JL, Gertz MA et al. Prognostic factors and response to fludarabine therapy in Waldenström’smacroglobulinemia: an update of a US Intergroup trial. Semin Oncol 2003; 30: 220-225.

23. Dimopoulos MA, Alexanian R. Waldenström’s macroglobulinaemia. Blood 1994: 83: 1452-1459.

24. Leblond V, Choquet S at al. Fludarabine in Waldenström’s macroglobulinemia. Semin Oncol 2003; 30: 239-242.

25. Johnson SA, Owen RG, Oscier DG et al. Phase III study of chlorambucil versus fludarabine as a initial therapy for Waldenström’s macroglobulinemia and related disorders. Clin Lymphoma 2005; 5: 294-297.

26. Enzenauer RJ, Judein PH. Purine analogues for treatment of refractory essentials mixed cryoglobulinemia. Mayo Clin Proc 1997; 72: 92-93.

27. Giudice I, Matutes E, Osuji N et al. Deleyed response to fludarabine in lymphoplasmocytic lymphoma/Waldenström’smacroglobulinemia. Hematologia 2005; 90: 268-270.

28. Dimopoulos MA, Kantarjian H, Weber D et al. Primary therapy of Waldenström’s macroglobulinaemia with 2-chlordeoxyadenosine. J Clin Oncol 1994; 12: 1694-2698.

29. Delannoy A, Van den Neste E, Michaux JL et al. Cladribine for Waldenström’s macroglobulinaemia. Brit J Haematol 1999; 104: 933-935.

30. Fridrik MA, Jater G, Baldinger C et al. First line treatment of Waldenström’sdisease with cladribine. Ann Hematol 1997; 74: 7-10.

31. Lewandowky K, Halaburda K, Hellman A et al. Fludarabine therapy in Waldenström’smacroglobulinemia patients treated previously with 2-chlordeoxyadenosine. Leuk Lymphoma 2002; 43: 361-363.

32. Lewandowski K, Zacha JM, Bieniaszewska M et al. 2-chlordeoxyadenosine treatment of Waldenström’smacroglobulinaemia. Med Sci Monit 2000; 6: 740-745.

33. Hampshire A, Saven A. Update of bolus administration of cladribine in the treatment of Waldenström’smacroglobulinemia. Blood 2003; 102(Suppl 1): 402.

34. Foran JM, Rohatiner AZS, Coffier B et al. Multicentre phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmocytic lymphoma, Waldenström’s macroglobulinaemia and mantle cell lymphoma. J Clin Oncol 1999; 17: 546-553.

35. Thalhammer S, Geissler K, Schwarzinger I et al. Fludarabine in Waldenström’s macroglobulinaemia. Ann Hematol 2000; 79: 775-779.

36. Dimopoulos MA, Weber D, Kantarjian H et al. 2-chlordeoxyadenosine therapy of Waldenström’s macroglobuliniaemia previously treated with fludarabine. Ann Oncol 1994; 5: 288-289.

37. Bettticher DC, Hsu DC, Schmitz SF et al. Cladribine given as subcutaneous bolus injection is active in pretreated macroglobulinaemia. Brit J Haematol 1997; 99: 358-363.

38. Dimopoulos MA, O’Brien S, Kantarjian H et al. Fludarabin therapy in Waldenström’s macroglobulinemia. Amer J Med 1993; 95: 49-52.

39. Leblond V, Ben-Othman T, Deconinck E et al. Activity of fludarabine in previously treated Waldenström’s macroglobulinaemia. J Clin Oncol 1998; 16: 2060-2064.

40. Zinzani PL, Gherlinzon F, Bendandi M et al. Fludarabine treatment in resistent Waldenström’s macroglobulinemia. Eur J Haematol 1995; 54: 120-123.

41. Tamburini JL, Chaleteix V, Cermane JP et al. Fludarabine plus cyclophoshamide in Waldenström’s macroglobulinemia. Results in 49 patients. Leukemie 2005; 19: 1831-1834.

42. Tam CS, Wolf M, Prince HM et al. Fludarabine, cyclophosphamide and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent lymphoma. Cancer 2006; 106: 2412-2420.

43. Weber DM, Dimopoulos MA, Dalasalle K et al. 2-chlordeoxyadenosine alone and in combination for previously untreated Waldenström’s macroglobulinemia. Semin Oncol 2003; 30: 243-247.

44. Bowcock SJ, Rassam SM, Lim Z et al. High incidence of therapy releated myelodysplasia and acute leukemia in general hematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders. Brit J Haematol 2006; 134: 242-243.

45. Leleu Y, Manning R, Soumerai J et al. Increased incidence of disease transformation and development of MDS/AML in Waldenström’s macroglobulinemia patients treated with nucleoside analogs. Haematologica 2007; 92(Suppl 2): WM3.10.

46. Leblond V. Role of purine analogs in front line treatment of Waldenström’s macroglobulinemia. Haematologica 2007; 92(Suppl 2): WM2.2.

47. Byrd JC, White CA, Link B et al. Rituximab therapy in Waldenström’s macroglobulinaemia. Ann Oncol 1999; 10: 1525-2527.

48. Capalbo S, Dargenio M, Delia M et al. Durable complete remission after chemotherapy and rituximab in a case of Waldenström’s macroglobulinemia with pleuropulmonaly involvement. Ann Hematol 2005; 84: 625-626.

49. Dimopoulos MA, Hamilos G, Efstathiou E et al. Treatment of Waldenström’s macroglobulinaemia with combination of fludarabine and cyclophosphamide. Leuk Lymphoma 2003; 44: 993-996.

50. Dimopoulos MA, Zervas C, Zomas A Extended rituximab therapy for previously untreated patients with Waldenstöm´s macroglobulinaemia. Clin Lymphoma 2002; 3: 163-166.

51. Dimopoulos MA, Anagnostopoulos A, Zervas C et al. Predictive factors for response to rituximab in Waldenström macroglobulinemia. Clin Lymphoma 2005; 5: 270-272

52. Foran JM, Rohatinek AZ, Cunningham D et al. European phase II study of rituximab for patients with newly diagnosed mantle cell lymphoma, imunocytoma and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317-324.

53. Gerz MA, Rue M, Blood E et al. Multicenter phase II trial of rituximab in Waldenström’s macroglobulinaemia. An Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004; 45: 2047-2055

54. Treon SP, Hunter ZR, Barnagan AR CHOP plus rituximab in Waldenström’s macroglobulinemia. Clin Lymphoma 2005; 5: 273-277.

55. Treon SP, Agus DB, Link B et al. CD20 directed antibody mediated immunotherapy induces response and facilitates hematologic recovery in patients with Waldenström’s macroglobulinaemia. J Immunother 2001; 24: 272-279.

56. Treon SP, Branagan AR, Hunter Z et al. Paradoxical increase in serum IgM viscosity levels following rituximab in Waldenström’s macroglobulinaemia. Ann Oncol 2004; 15: 1481-1483.

57. Treon SP, Emmanoulides C, Kimby E et al. Extended rituximab therapy in Waldenström’s macroglobulinaemia. Ann Oncol 2005; 16: 132-138.

58. Treon SP, Hansen M, Branagan AR et al. Polymorphismus in FCgama (CD16) receptor expression are associated with clinical response to rituximab in Waldenström macroglobulinemia. J Clin Oncol 2005; 23: 474-481.

59. Treon SP, Kelliher A, Keele B et al. Expression of serotherapy targets in Waldenström’s macroglobulinaemia. Therapeutic application and consideration. Semin Oncol 2003; 30: 248-252.

60. Emmanoulides Ch Radioimmunotherapy for Waldenström’s macroglobulinamia. Semin Oncol 2003; 30: 258-261.

61. Tsai DE, Maillard I, Wowns LH et al. Use of iodine 131I tositumomab radioimmunotherapy in a patients with Waldenström’s macroglobulinaemia. Leuk Lymphoma 2004; 45: 591-595.

62. Krishna VM, Carey RW, Bloch KJ Marked increase in serum IgM during treatment of Waldenström’s macroglobulinemia with cladribine N Engl J Med 2003; 348: 2045-2046.

63. Ghobrial IR, Fonseca R, Greipp PR et al. Initial imunoglobulin M flare after rituximab therapy in patients diagnosed with Waldenström’s macroglobulinaemia. Cancer 2004; 101: 2593-2598.

64. Nichols GL, Sabate DG Timing of Rituximab/Fluradarabine in Waldenström’s macroglobulinaemia may influence hyperviscosity. Blood 2004; 104(Suppl): 237b

65. Weber DM, Thomas S, Wang M et al. Rituximab alone or in combination in the frontline treatment of Waldenström’s macroglobulinemia. Haematologica 2007; 92(Suppl. 2): WM2.3.

66. Weber DN, Dimopoulos MA, Dellasale J. 2-chlordeoxyadenosine alone and in combination for previsously untreated Waldenström’s macroglobulinaemia. Semin Oncol 2003; 30, 243-247.

67. Treon SP, Wasi P, Emmanoulides CA. Combination therapy with rituximab and fludarabine is highly active in Waldenström’s macroglobulinemia. Blood 2002; 100(Suppl 1): 211.

68. Kilidireas C, Anagnastopoulos A, Karandreas N et al. Rituximab therapy in monoclonal IgM releated neuropaties. Leuk Lymphoma 2006; 47: 859-864.

69. Laszlo A, Andreola G, Rabascio C et al. Cladribine and rituximab combination treatment for patients with Waldenström’s macroglobulinemia or small lymphocytic lymphoma. Haematologica 2007; 92(Suppl 2): Po 1224 (abstr).

70. Pearlman AN, Fechner F, Constantinides M Development of nasal skin necrosis associated with rituximab treatment for Waldenström’s macroglobulinemia and subsequent spontaneuous resolution. Ear Nose Throat Journal 2006; 85: 431-433

71. Tedeschi A, Miqueleiz AS, Ricci F et al. Fludarabine cyclophosphamide and rituximab an effective regimen characterized by high incidence of delayed responses in Waldenström’s macroglobulinaemia. Haematologica 2007; 92(Suppl 2): Po 1225 (abstr).

72. Thomas SK, Delassale KB, Gavino M et al. 2-CDA cyclophosphamide plus rutuximab for symptomatic WM. Haematologica 2007; 92(Suppl 2): Po 1227 (abstr).

73. Vargaftig J, Pegourie-Bandelier B, Mahe B et al. Fludarabine plus cyclophosphamide and rituximab in Waldenström’s macroglobulinemia. Results in 25 patients. Haematologica 2007; 92(Suppl 2): Po 1226 (abstr).

74. Treon ST, Hunter Z, Branagan AR CHOP plus rituximab therapy in Waldenström’s macroglobulinaemia. Clin Lymphoma 2005; 5: 273-277.

75. Owen RG, Rawstron AC, Osterborg A et al. Activity of alemtuzumab in relapsed/refraktory Waldenström’s macroglobulinaemia. Blood 2003; 644: Suppl. 645.

76. Owen RG, Hillmen P, Rastron AC CD52 expression inWaldenström’s macroglobulinaemia: Implication for alemtuzumab therapy and response assessment. Clin Lymphoma 2005; 5: 278-281.

77. Santos DD, Hatjiharisi E, Tournilhac O et al. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 2006; 6: 478-483.

78. Tournilhac O, Santos DD, Xu L et al. Mast cells in Waldenström’s macroglobulinemia support lymphoplasmocytic cell growth trough CD154/CD40 signaling. Ann Oncol 2006; 17: 1275-1282.

79. Treon SR. CD52 is expressed on human mast cells and is a potentional therapeutic target in Waldenström’s macroglobulinaemia and mast cell disorders. Clin Lymphoma Myeloma 2006; 6: 470-473.

80. Owen RG, Hillmen P, Rastron AC. CD52 expression inWaldenström’s macroglobulinaemia: Implication for alemtuzumab therapy and response assessment. Clin Lymphoma 2005; 5: 278-281.

81. Branagan AR, Hunter Z, Santos D et al. Thalidomide and rituximab in Waldenström macroglobulinaemia. Blood 2004; 104: 415.

82. Coleman M, Leopard J, Lyons L et al. Treatment of Waldenström’s macroglobulinemia with claritromycin, low-dose thalidomid and dexamethasone. Semin Oncol 2003; 30: 270-274.

83. Dimopoulos MA, Tsatalas A, Zomas G Treatment of Waldenström’s macroglobulinaemia with single agent thalidomid or with the combination of clarithromycin, thalidomid and dexamethasone. Semin Oncol 2003; 30: 265-269.

84. Dimopoulos MA, Zomas A, Viniou NA. Treatment of Waldenström macroglobulinemia with thalidomide. J Clin Oncol 2001; 19: 3596-3601.

85. Soumerai J, Branagan A, Hunter Z et al. Use of the immunomodulators thalidomide and lenalidomide tu augment rituximab activity in Waldenström’s macroglobulinaemia. Haematologica 2007; 92(Suppl 2): WM3.8 (abstr).

86. Strauss SJ, Maharaj L, Stec J et al. Phase II study of bortezomib in patients with relapsed/refraktory non-Hodgkin’s disease. Blood 2004; 104: 389.

87. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC et al. Treatment of relapsed or refractory Waldenström macroglobulinaemia with bortezomib. Haematologica 2005; 90: 1655-1658.

88. Gertz MA, Zeyer SM, Badros A. Early results of phase I of oblimersen sodium for relapsed or refractory Waldenström’s macroglobulinemia. Clin Lymphoma 2005; 5: 282-284.

89. Frankel SR. Oblimersen sodium therapy in Waldenström’s macroglobulinaemia. Semin Oncol 2003; 30: 300-304

90. Treon SP, Tournihac O, Branagan AR et al. Clinical response to sildenafil in Waldenstöm´s macroglobulinemia. Clin Lymphoma 2004; 5: 205-207.

91. Anagnostopoulos A, Dimopoulos MA, Aleman A et al. High dose chemotherapy followed by stem cell transplantation in patients with Waldenström’s macroglobulinemia. Bone Marrow Transplant 2001; 27: 1027-1029.

92. Anagnostopoulos A, Aleman A, Gorale S et al. Autologous and allogenic stem cell transplantation in Waldenström’s macroglobulinemia. Semin Oncol 2003; 30: 286-290.

93. Anagnostopoulos A, Parameswaran N, Waleska HH et al. Augologous or allogeneic stem cell transplantation in patients with Waldenström’s macroglobulinemia. Biol Blood Marrow Transplant 2006; 12: 845-854.

94. Tournilhac O, Leblond V, Tabrizi R et al. Transplantation in Waldenström’s macroglobulinaemia. The French Experience. Semin Hematol 2003; 30: 291-296.

95. Munshi NC, Barlogie B. Role of high dose therapy with autologou hematopoietic stem cell support in Waldenström’s macroglobulinaemia. Semin Oncol 2003; 30: 282-285.

96. Kyriakou C, Canals C, Taghipour G et al. Allogeneic stem cell transplantation in Waldenström macroglobulinaemia. An analysis of 106 cases from the European Bone Marrow Transplatn registry. Haematologica 2007; 92(Suppl 2): WM3.9 (abstr).

97. Kyriakou C, Canals C, Taghipour G et al. Autologous stem cell transplantation for patients with Waldenström’s macroglobulinaemia. An analysis of 201 cases from the European Bone Marrow Transplant registry. Haematologica 2007; 92(Suppl 2): 1228 (abstr).

98. Han PN. Autologous and allogeneic stem cell transplantation in patients with Waldenström’s macroglobulinemia. Biol Blood Marrow Transplant 2006; 12: 845-854.

99. Dreger P, Glass B, Kuse R et al. Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cell for Waldenström’s macroglobulinaemia Brit J Hematol 1999; 106: 115-118.

100. Desikan MV, Dhodapkar M, Siegel D et al. High dose therapy with autologous hemopoietic stem cell support for Waldenström macroglobulinaemia. Brit J Haematol 1999; 105: 993-996

101. Yang L, Wen B, Li H et al. Autologous peripheral stem cell transplantation for Waldenström’s macroglobulinemia. Bone Marrow Transplant 1999; 24: 929-930.

102. Johnson SA. Advances in the treatment of Waldenström’s macroglobulinemia. Exp Rev Anticancer Treatment 2006; 6: 329-334.

103. Clark WF, Rock GA, Buskard N et al. Therapeutic plasma exchange: an update from the Canadian Apheresis Group. Ann Intern Med 1999; 131: 453-462.

104. Dimopoulos MA. Rituximab therapy in monoclonal IgM related neuropaties. Leuk Lymphoma 2006; 47: 859-864.

105. Dyck PJ, Low PA, Windeband AJ et al. Plasma exchange in polyneuropathy associated with monoclonal gammapathy of undetermined significance. J Engl J Med 1991; 325: 1482-1486.

106. Einstein R. Therapeutic plasma exchange performed in tandem with hemodialysis for patients with M-protein disorders. J Clin Apheresis 2006; 21: 100-104.

107. Gertz MA. Waldenström’s macroglobulinemia: review of therapy. Amer J Hematology 2005; 79: 147-157.

108. Gordon KC. Clinical features evaluation, and treatment of paraproteinemic neuropathy associated with gammapathy of undetermined significance J Clin Apheresis 1999; 14: 149-153.

109. Hadden RDM. European Federation of Neurological Societies, Peripheral nerve society guideline on management of paraproteinemic demyelinating neuropaties. Eur J Neurology 2006; 13: 809-818.

110. Kazkaz H, Isenberg D. Anti B-cell therapy in the treatment of autoimmune disease. Curr Opin Pharmacol 2004; 4: 398- 402

111. Kiprov D, Hofmann JC. Plasmapheresis in immunologicaly mediated polyneuropaties. Ther Apher Dial 2003; 7: 189-196.

112. Levine T, Pestron A, Florence J et al. Peripheral neuropathies in Waldenström’s macroglobulinemia. J Neurol Neurosurg Psychiatry 2006; 77: 224-228.

113. Liberato B, Riethmuller A, Comenzo RL et al. Myelopathy from Waldenström’s macroglobulinaemia: improvement after rituximab therapy. J Neurooncol 2003; 63: 207-211.

114. Lunn MPT, Nobile-Ozario E. Immunotherapy for IgM anti-myelin associated glycoprotein paraprotein-associated peripheral neuropaties. To Cochrane Library 2006 (4); www.thecochranelibrary.com

115. Nobile-Orazio E. IgM paraproteinemic neuropathies. Curr Opin Neurol 2004; 17: 599-605.

116. Nobile-Ozario E. Immunotherapy for IgM anti-myelin associated glycoprotein associated peripheral neuropathies. The Cochrane library 2006 (4).

117. Owen RG, Parapia LA, Higginson J et al: Clinicopathological correlates of IgM paraproteinemias. Clin Lymphoma 2000; 1: 39-43.

118. Pestrong A, Florence J, Miller T et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurgery Psychiatr 2003; 74: 485-489.

119. Pestronk A. Peripheral neuropathy in Waldenström’s macroglobulinemia. J Neurol Neurosurg Psychiatr 2006; 77: 224-228.

120. Latow N. Prognosis of neuropathy with monoclonal gammopathy. Musle Nerve 2000; 23: 150-152.

121. Simovic D, Gorson, KC, Ropper AH. Comparison of IgM-MGUS and IgG MGUS polyneuropathy. Acta Neurol Scand 1998; 97: 194-200.

122. Weber DM, Gavino M, Huh Y et al. Phenotypic and clinical evidence supports rituximab for Waldenstöm´s macroglobulinaemia. Blood 1999; 94(Suppl 1): ???Abstr???.

123. Weide R, Heymanns J, Koppler H The polyneuropathy associated with Waldenström’s macroglobulinaemia can be treated effectively with chemotherapy and anti CD20 monoclonal antibody. Brit J Haematol 2000; 109: 838-841.

124. Wicklund MP, Kissel JT. Paraproteinemic neuropaty. Curr Treat Options Neurol 2001; 3: 147-156.

125. Koning HD, Bodar EJ, Simon A et al. Beneficial response to anakinra and thalidomide in Schnitzler’s syndrome. Ann Rheum Dis 2006; 65: 542-544.

126. Schnitzler L, Hurez D, Verret JL et al. Chronic urtika and hyperostosis in macroglobulinemia. Ann Dermatol Venereol 1989; 116: 547-550.

127. Bryce AH, Dispenzieri A, Kyle R et al. Response to rituximab in patients with type II cryoglobulinaemia. Clin Lymphoma 2006; 7: 140-144.

128. Bryce AH, Kyle RA, Dispenzieri A et al. Natural history of therapy of 66 patients with mixed cryoglobulinemia. Amer J Hematol 2006; 81: 511-518.

129. Dimopoulos MA, Panayiotis P, Moulapoulos LA et al. Waldenström’s makroglobulinemia: Clinical features, complication and management. J Clin Oncol 2000; 18: 214-226.

130. Dispenzeri A. Symptomatic cryoglobulinemia. Curr Treat Option Oncol 2000; 2: 105-118.

131. Enzenauer RJ, Judein PH Type II mixed cryoglobulinaemia treated with fludarabine. J Rheamatol 1996; 23: 764-795.

132. Gertz MA. Natural history and therapy of 66 patients with mixed cryoglobulinemia. Amer J Hematol 2006; 81: 511-518.

133. Gertz MA Overview in salvage treatment in Waldenström’s macroglobulinemia. Haematologica 2007; 92(Suppl 2): WM2.4 (abstr).

134. Roccatelo D, Baldvino S, Rossi D et al. Long-term effects of antiCD20 monoclonal antibody treatment of cryoglobulinemic glomerulonefritis. Nephrol Dial Transplant 2004; 30: 543-561.

135. Zaja F, DeVita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinaemia. Blood 2003; 101: 3827-3840.

136. Gobi PG, Bettini R, Montecucco C et al. Study of prognosis in Waldenström’s macroglobulinaemia. Blood 1994; 83: 1452-1459.

137. Jacobs A A cold aglutinin hemolysis responding to fludarabine therapy. Am J Hematol 1996; 53: 279-280.

138. Berentsen S, Ulvestad E, Gjertsen BT et al. Rituximab for primary chronic cold agglutinin disease. Prospective study of 37 courses of therapy in 27 patients. Blood 2004; 103: 2925-2928.

139. He1lmann A, Lewandowky I, Zaucha JM. Effect of 2-hour infusion of 2-chlordeoxyadenosine in the treatment of previously untreated Waldenström’s macroglobulinemia. Brit J Hematol 1999; 104: 933-934.

140. Laurince FM, Zulian GB, Ghetty A et al. Cladribin with cyclophoshamide and prednisone in the management of low grade lymphoproliferative malignancies. Brit J Cancer 1999; 79: 1215-1219.

141. Tam CS, Wolf MM, Westerman D et al. Fludarabine combination therapy is highly effective in fist line and salvage treatment of patients with Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma 2005; 6: 136-139.

142. Tam CS, Seymour JF, Prince JM. Treatment releated myelodysplasia following fludarabine combinations chemotherapy. Haematologica 2006; 91: 1546-1550.

143. Treon SP. Mast cells in Waldenström’s macroglobulinaemia support lymphoplasmocytic cell growth through CD154CD40 signaling. Ann Oncol 2006; 17: 1275-1282.

144. Treon SP. Update on recommendation for assessing response from the Third International Workshop on Waldenström’s macroglobulinaemia. Clin Lymphoma Myeloma 2006; 6: 380-383.

145. Treon SP, Gertz MA, Dimopoulos M et al. Update on treatment recommendations from the Third International Worshop on Waldenström’s macroglobulinaemia. Blood 2006; 107: 3442-3446.

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 1

2008 Issue 1

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#